Abstract
Voltage-gated sodium channels (NaV) are well validated targets for treating pain based both on human genetics and clinical experience. Consequently, there is an extensive literature on sodium channels for the treatment of pain and a number of excellent and thorough reviews have recently appeared; a selection of these is provided. This review does not attempt to evaluate all aspects of the studies in this area, but rather will focuses on several key issues that are incompletely addressed in prior reviews or that represent very recent additions to the literature. Key questions that arise are: 1) How much channel block is required to observe efficacy against neuropathic or inflammatory pain? 2) How can one improve upon the therapeutic index of previously tested NaV blockers?
Keywords: Analgesia, NaV, pain, voltage-gated sodium channel, channel block, efficacy, neuropathic or inflammatory pain, therapeutic index, ANALGESIC ACTIVITY, inflammed tissue, PET ligands
Current Pharmaceutical Biotechnology
Title: Targeting Voltage-Gated Sodium Channels for Treating Neuropathic and Inflammatory Pain
Volume: 12 Issue: 10
Author(s): Charles J. Cohen
Affiliation:
Keywords: Analgesia, NaV, pain, voltage-gated sodium channel, channel block, efficacy, neuropathic or inflammatory pain, therapeutic index, ANALGESIC ACTIVITY, inflammed tissue, PET ligands
Abstract: Voltage-gated sodium channels (NaV) are well validated targets for treating pain based both on human genetics and clinical experience. Consequently, there is an extensive literature on sodium channels for the treatment of pain and a number of excellent and thorough reviews have recently appeared; a selection of these is provided. This review does not attempt to evaluate all aspects of the studies in this area, but rather will focuses on several key issues that are incompletely addressed in prior reviews or that represent very recent additions to the literature. Key questions that arise are: 1) How much channel block is required to observe efficacy against neuropathic or inflammatory pain? 2) How can one improve upon the therapeutic index of previously tested NaV blockers?
Export Options
About this article
Cite this article as:
J. Cohen Charles, Targeting Voltage-Gated Sodium Channels for Treating Neuropathic and Inflammatory Pain, Current Pharmaceutical Biotechnology 2011; 12 (10) . https://dx.doi.org/10.2174/138920111798357249
DOI https://dx.doi.org/10.2174/138920111798357249 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Discovery of Anticoagulant Drugs: A Historical Perspective
Current Drug Discovery Technologies Disturbance of Apolipoprotein B100 Containing Lipoprotein Metabolism in Severe Hyperlipidemic and Lipodystrophic HIV Patients on Combined Antiretroviral Therapy: Evidences of Insulin Resistance Effect
Medicinal Chemistry Major Mental Disorders and Violence: A Critical Update
Current Psychiatry Reviews Establishing Genomic/Transcriptomic Links Between Alzheimer’s Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach
CNS & Neurological Disorders - Drug Targets Hemolysis-Associated Pulmonary Hypertension in Sickle Cell Disease: Global Disruption of the Arginine-Nitric Oxide Pathway
Current Hypertension Reviews Mimetics of the Peptide β-Strand
Mini-Reviews in Medicinal Chemistry The Protective Role of Steroids in Ischemia-Reperfusion Injury of the Liver
Current Pharmaceutical Design Pulmonary Involvement in Inflammatory Bowel Disease
Current Drug Targets - Inflammation & Allergy T-type Calcium Channels in Health and Disease
Current Medicinal Chemistry Advances in Sickle Cell Disease Treatment: from Drug Discovery Until the Patient Monitoring
Cardiovascular & Hematological Agents in Medicinal Chemistry Bridging the Gap Between Chemistry and Biotechnology - Large Molecules with Potential, How Could Biotechnology Complement Chemistry?
Current Organic Chemistry The Role of Transcription Factors in the Formation of an Arrhythmogenic Substrate in Congestive Human Heart Failure
Current Medicinal Chemistry Introduction to the Special Issue “Pharmacotherapies for the Treatment of Alcohol Abuse and Dependence” and a Summary of Patents Targeting other Neurotransmitter Systems
Recent Patents on CNS Drug Discovery (Discontinued) CXC Chemokines in Angiogenesis Relevant to Chronic Fibroproliferation
Current Drug Targets - Inflammation & Allergy Are we Genomic Mosaics? Variations of the Genome of Somatic Cells can Contribute to Diversify our Phenotypes
Current Genomics Biomarker Approach Towards Rheumatoid Arthritis Treatment
Current Rheumatology Reviews The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome
Current Pharmaceutical Design Cardioprotection by Regular Ethanol Consumption: Potential Mechanisms and Clinical Application
Current Drug Abuse Reviews Inflammation-Associated Changes in Bone Homeostasis
Inflammation & Allergy - Drug Targets (Discontinued) The Efficacy of Conceptual DFT Descriptors and Docking Scores on the QSAR Models of HIV Protease Inhibitors
Medicinal Chemistry